Oncotalks | Powered by Novartis

Section 2: Melanoma Therapy during COVID-19 Pandemic - Focus on Adverse Events (Prof. Dirk Schadendorf)

Switzerland , Hungary

00:14:44

Section 3: Cancer patients are at increased risk for COVID-19 - Learnings from Wuhan (Prof. Dirk Schadendorf)

Switzerland , Hungary

00:04:31

Section 5: Q&A (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

Switzerland , Hungary

00:23:47

Full Video: Meet the Experts: Melanoma therapy during COVID-19 pandemic (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

Full Video: Meet the Experts: Melanoma therapy during COVID-19 pandemic (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)The Virtual Meet the expert Event took place on the 14th of April 2020Swiss approval code:1332629

Switzerland , Hungary

00:57:38

Section 1: Welcome and Introduction (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

Section 1: Welcome and Introduction (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)The Virtual Meet the expert Event took place on the 14th of April

Switzerland , Hungary

00:02:45

PD Dr. med. Wolfgang Willenbacher - Case Presentation on Systemic Mastocytosis

PD Dr. med. Wolfgang Willenbacher, Universitätsklinik Innsbruck, Austria, presenting on systemic mastocytosis at an educational event in Zurich, Switzerland, October 2019Swiss: P3: C12003810939

Switzerland

00:10:03

Section 9: ITP Therapy - Thrombopoietin Receptor Agonists (TPO-RA) and Rituximab

Related items

Section 2: Melanoma Therapy during COVID-19 Pandemic - Focus on Adverse Events (Prof. Dirk Schadendorf)

Section 3: Cancer patients are at increased risk for COVID-19 - Learnings from Wuhan (Prof. Dirk Schadendorf)

Section 5: Q&A (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

Full Video: Meet the Experts: Melanoma therapy during COVID-19 pandemic (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

Section 1: Welcome and Introduction (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

PD Dr. med. Wolfgang Willenbacher - Case Presentation on Systemic Mastocytosis

Section 9: ITP Therapy - Thrombopoietin Receptor Agonists (TPO-RA) and Rituximab

Related items

Section 2: Melanoma Therapy during COVID-19 Pandemic - Focus on Adverse Events (Prof. Dirk Schadendorf)​

Section 3: Cancer patients are at increased risk for COVID-19 - Learnings from Wuhan (Prof. Dirk Schadendorf)​

Section 5: Q&A (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

Full Video: Meet the Experts: Melanoma therapy during COVID-19 pandemic (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)​

Section 1: Welcome and Introduction (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)

PD Dr. med. Wolfgang Willenbacher - Case Presentation on Systemic Mastocytosis

Section 2: Melanoma Therapy during COVID-19 Pandemic - Focus on Adverse Events (Prof. Dirk Schadendorf)

Section 3: Cancer patients are at increased risk for COVID-19 - Learnings from Wuhan (Prof. Dirk Schadendorf)

Full Video: Meet the Experts: Melanoma therapy during COVID-19 pandemic (Prof. Reinhard Dummer & Prof. Dirk Schadendorf)